XELEVIA 100 mg, film-coated tablet 30 tablets
Active ingredients: Sitagliptin phosphate hydrate, Sitagliptin
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XELEVIA 100 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s)
- Marketing authorisation holder
- MERCK SHARP & DOHME (PAYS-BAS)
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 22 Aug 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65602428CIP72788765CIP133400927887659Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SITAGLIPTINEcomprimé | 100 mg · un comprimé | FT |
| PHOSPHATE DE SITAGLIPTINE MONOHYDRATÉcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.